TargetMol

FL3

Product Code:
 
TAR-T27330
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27330-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27330-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27330-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
FL3 is a novel potent eIF4F inhibitor, it induces the death of cancer cells by an original mechanism that involves the apoptosis-inducing factor and caspase 12.
CAS:
1186012-80-5
Formula:
C25H23BrO5
Molecular Weight:
483.358
Purity:
0.98
SMILES:
COc1cc2O[C@]3([C@@H](C[C@@H](O)[C@@]3(O)c2c(OC)c1)c1ccccc1)c1ccc(Br)cc1

References

1. El Behery R, Laurini JA, Weisenburger DD, Smith LM, Dave BJ, Yuan J, Fu K, Chan WC, Nathwani BN, Bierman PJ, Bociek RG, Vose JM, Armitage JO, Greiner TC, Aoun P. Follicular large cleaved cell (centrocytic) lymphoma: An unrecognized variant of follicular lymphoma. Hum Pathol. 2017 Nov 20. pii: S0046-8177(17)30408-2. doi: 10.1016/j.humpath.2017.11.002. [Epub ahead of print] PubMed PMID: 29170017. 2. Li Q, Wang J, Ye J, Zheng X, Xiang X, Li C, Fu M, Wang Q, Zhang Z, Wu Y. The Maize Imprinted Gene Floury3 Encodes a PLATZ Protein Required for tRNA and 5S rRNA Transcription through Interaction with RNA Polymerase III. Plant Cell. 2017 Oct;29(10):2661-2675. doi: 10.1105/tpc.17.00576. Epub 2017 Sep 5. PubMed PMID: 28874509. 3. Yuan J, Greiner TC, Fu K, Smith LM, Aoun P, Chan WC, Bierman PJ, Bociek RG, Vose JM, Armitage JO, Weisenburger DD. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy. Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):488-497.e2. doi: 10.1016/j.clml.2017.06.006. Epub 2017 Jun 16. PubMed PMID: 28842137. 4. Mustafa Ali M, Rybicki L, Nomani L, Rouphail B, Dean RM, Hill BT, Jagadeesh D, Pohlman B, Hsi ED, Smith MR. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):797-803. doi: 10.1016/j.clml.2017.07.002. Epub 2017 Jul 13. PubMed PMID: 28789937.